Incyte

Incyte will be presenting data from our Hematology and Oncology pipeline at the 2026 @EHA_Hematology Congress in Stockholm. Stay tuned for updates and read more about our data. #EHA2026 bit.ly/430KoCf

At this year’s #EADVSymposium, we shared data in patients with moderate atopic dermatitis (AD). Learn more about these data. bit.ly/4uz96Wa

At Incyte, we’re committed to advancing research and solutions to help address patient needs and preferences. We are proud to announce the @US_FDA approval of a new, once-daily formulation of our therapy for MPNs and GVHD. Learn more. bit.ly/4et7KHU

Learn more about Incyte’s latest @US_FDA approval of a bioequivalent, once-daily formulation of our therapy for patients living with certain types of myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). bit.ly/4uxk6Ua

We are excited to welcome David Brooks, M.D., who joins #TeamIncyte today as Group Vice President of Global Medical Affairs. David brings deep medical leadership experience, and a strong perspective on the critical role Medical Affairs plays in advancing care.

Welcome to #TeamIncyte, Nicole Katz! Nicole joins as Group Vice President, Head of Global Corporate Affairs, and is a seasoned global communications and corporate affairs leader with more than 25 years of experience across a broad range of therapeutic areas.

Please join us in welcoming Suketu (Suky) Upadhyay to #TeamIncyte! Suky was recently appointed Executive Vice President and Chief Financial Officer (CFO). He brings extensive experience in the healthcare sector and a strong track record of leading high-performing finance organizations. bit.ly/4w7Yy1H

The @US_FDA has approved a once-daily formulation of our treatment for patients with certain types of myeloproliferative neoplasms (MPNs) and graft-versus-host disease (GVHD). Read our press release to learn more about this significant milestone. bit.ly/4w9Euw8

As shared this morning during our Q1 2026 earnings call, we announced positive Phase 3 results from our STOP-V clinical trial program in adult patients with nonsegmental vitiligo. Read our press release to learn more. bit.ly/4mT5HPc

Read our press release for Incyte’s Q1 2026 financial results and business updates. bit.ly/4u6UUn8

We’re headed to @ASCO where new data from our oncology portfolio will be presented. Read our press release to learn more about our presence at #ASCO26. bit.ly/4cSIucF

Our team had a great time attending #AAD2026 in Denver! It was a meaningful weekend engaging with the dermatology community.

At @AADskin’s Annual Meeting we presented new data in hidradenitis suppurativa, atopic dermatitis and vitiligo. #AAD2026 bit.ly/4sFDoGi

At the @AADskin’s Annual Meeting, we presented new late-breaking 54-week data for patients with moderate to severe hidradenitis suppurativa (HS). Learn more. #AAD2026 bit.ly/4bU12aY

Join Incyte at the @AADskin 2026 Annual Meeting this weekend to explore how Incyte is advancing innovation in dermatology for patients. Learn more. #AAD2026 bit.ly/4bDD2Kk

Learn more about the new late-breaking 54-week hidradenitis suppurativa (HS) data and other abstracts being presented from our dermatology portfolio at this year’s @AADskin Annual Meeting. #AAD2026 bit.ly/4svtlDr

Incyte to present new data from its dermatology portfolio at the @AADskin Annual Meeting. #AAD2026 bit.ly/4rNhdgb

#News: Incyte receives approval of a treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) from the @EU_Commission. Read to learn more. bit.ly/4lfcthD

Read our press release for Incyte’s Q4 and FY2025 financial results and updates on our key clinical programs. bit.ly/4apRJ1K

At the @JPMorgan Healthcare Conference this week, we shared how we’re transforming into a high-growth company. Download the presentation and listen to the recording here. #JPM2026 bit.ly/4sOJ9SA